Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement

Mar

05

Today In Oncology

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

CD123-Targeting ADC Shows Activity in AML and BPDCN

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers

Advertisement

© 2026 HSP News Service, L.L.C.